Our website uses cookies. We use cookies to remember settings and to help provide you with the best experience we can. We also use cookies to continuously improve our website by compiling visitor statistics. Read more about cookies

Lieve Tytgat

Principal Investigator
Lieve Tytgat
Lieve Tytgat
Dr. Lieve Tytgat leads a research group in the Princess Máxima Center.

Lieve Tytgat studied medicine at the university of Amsterdam, in 1995 she passed cum laude for her medical doctor exams. After this she combined the training to become a pediatrician with PhD studies. Under supervision of prof Voute she defended her thesis in 2001, and successfully finished her pediatric training. She became a fellow of the Dutch Cancer Society, trained as pediatric oncologist in the Netherlands and she also acquired the French pediatric oncology diploma the “DIUOP” (Diplome Interuniversitaires D'Oncologie Pédiatrique) in 2003. From 2003 – 2008 she worked in the Zaans Medisch Centrum; from 2008 – 2015 in the Academic Medical Center (pediatric oncology); from 2015 – now in the Princess Maxima Center for pediatric oncology.

Awards & Honors

1988 Young Investigator Awards: Advances in neuroblastoma research (Bath, England).

Fellow of the Koningin Wilhelmina Fonds, Dutch Cancer Society

Personal KWF grant for Molecular tumor response monitoring of neuroblastoma patients to support treatment stratification and new drug development

Research Focus

Her main focus is on translational studies in neuroblastoma and other solid tumors, with emphasis on liquid biopsy applications to support clinical care. She is active in national and international neuroblastoma disease committees, and currently chairs the International GPOH/DCOG Prospective MRD Study group, the Dutch Neuroblastoma Protocol Committee and SIOPEN HR Protocol Committee. She was a member of the Bone Marrow Revised-INRG working group, a member of the Regional Advanced Neuroblastoma committee. Under her supervision, five PhD students successfully defended their theses on different topics and currently 6 PhD students are performing their research.

  • Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapy

    • feb. 2024
    • Judith, Wienke, et al
    • Cancer Cell
  • Incidence and survival of paediatric renal tumours in the Netherlands between 1990 and 2014

    • nov. 2022
    • Maya, Schulpen, et al
    • European Journal of Cancer
  • Chromosome 11q loss and MYCN amplification demonstrate synthetic lethality with checkpoint kinase 1 inhibition in neuroblastoma

    • sep. 2022
    • Kaylee M., Keller, et al
    • Frontiers in Oncology
  • Mutational spectrum of ATRX aberrations in neuroblastoma and associated patient and tumor characteristics

    • jun. 2022
    • Michael R., van Gerven, et al
    • Cancer Science
  • Thyroid function after diagnostic <sup>123</sup>I-metaiodobenzylguanidine in children with neuroblastic tumors

    • jun. 2022
    • Sarah C., Clement, et al
    • Annals of Nuclear Medicine
View all publications